Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Yantai Zhenghai Biotechnology Co., Ltd. specializes in the production of high-quality biopharmaceuticals, particularly in the field of immunotherapy and vaccines. The company operates primarily in China, leveraging its advanced R&D capabilities and a strong patent portfolio to maintain a competitive edge in the rapidly evolving biotech sector.
Yantai Zhenghai generates revenue primarily through the sale of proprietary biopharmaceutical products, which are priced at a premium due to their innovative nature and clinical efficacy. The company benefits from strong pricing power, supported by its robust patent portfolio and established relationships with healthcare providers and government agencies.
Regulatory approvals for new drugs, particularly in immunotherapy
Partnership announcements with major pharmaceutical companies
Clinical trial results that exceed expectations
Changes in government healthcare policies affecting biotech funding
Regulatory changes that could impact drug approval processes
Technological disruptions in biopharmaceutical manufacturing
Emerging biotech firms with innovative therapies
Established pharmaceutical companies entering the immunotherapy space
Low liquidity risk due to a current ratio of 8.42
Potential future cash flow pressures if revenue growth does not improve
moderate - The biotechnology sector is somewhat insulated from economic downturns, but funding for R&D can be sensitive to overall economic conditions.
Higher interest rates can increase the cost of capital for R&D investments, potentially slowing down expansion plans and impacting valuation multiples.
minimal - The company has a very low debt/equity ratio of 0.01, indicating strong financial stability.
growth - Investors looking for high-growth opportunities in the biotech sector will be attracted to Yantai Zhenghai's innovative product pipeline.
high - The stock has experienced significant volatility, with a 1-year return of -28.7%, indicating a high-risk profile.
